Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.

An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.

Allergy Therapeutics says it has learned lessons from its failed Phase III birch pollen allergy trial and is applying those to its pivotal grass Phase III study.

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.